This NDC is on FDA's drug shortage list (posted Oct 12, 2022)

Product Information

DEXTROAMP-AMPHETAM 12.5 MG TAB is a generic product labeled by Sunrise Pharmaceutical Inc., priced at $0.3509 per EA under NDC 11534019301. Its NADAC has been published 323 times since Sep 9, 2020.

FDA first approved this application on Dec 28, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

DEA Schedule CII

Strength

3.125; 3.125; 3.125; 3.125 mg/1; mg/1; mg/1; mg/1

NDC

11534019301

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

10/21/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA209799

FDA Approved

12/28/2017

TE Code

AB

On Market Since

7/4/2018

Pharmacological Classes

Central Nervous System Stimulant
Central Nervous System Stimulant
Central Nervous System Stimulant
Central Nervous System Stimulant
Central Nervous System Stimulation
Central Nervous System Stimulation
Central Nervous System Stimulation
Central Nervous System Stimulation

Price Statistics

The NADAC for DEXTROAMP-AMPHETAM 12.5 MG TAB has been published 323 times since Sep 9, 2020, and over the history we have for it it has declined 52.0%. The table below summarizes its recorded NADAC range and movement.

Current price$0.3509 per EA
All-time high$0.8057 (Jun 16, 2021)
All-time low$0.2862 (Nov 20, 2024)
52-week high$0.3592
52-week low$0.3065
Median price$0.4978
Average price$0.4980
Largest weekly change+70.2% (Dec 21, 2022)
Weeks tracked323
Tracking sinceSep 9, 2020

Price History

1W

0.0%

1M

-2.3%

3M

+1.9%

6M

+14.5%

1Y

+2.5%

3Y

-32.8%

5Y

-46.9%

All

-52.0%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of DEXTROAMP-AMPHETAM 12.5 MG TAB?

The current National Average Drug Acquisition Cost (NADAC) for DEXTROAMP-AMPHETAM 12.5 MG TAB, manufactured by Sunrise Pharmaceutical Inc., is $0.3509 per EA (NDC 11534019301), effective Nov 11, 2026.

How has the price of DEXTROAMP-AMPHETAM 12.5 MG TAB changed over time?

Over the history we have for it, the NADAC for DEXTROAMP-AMPHETAM 12.5 MG TAB has declined 52.0%. It has been tracked across 323 weekly CMS publications since Sep 9, 2020.

What are the highest and lowest recorded NADAC prices for DEXTROAMP-AMPHETAM 12.5 MG TAB?

Since Sep 9, 2020, the NADAC for DEXTROAMP-AMPHETAM 12.5 MG TAB has ranged from a low of $0.2862 (Nov 20, 2024) to a high of $0.8057 (Jun 16, 2021), with a median of $0.4978 per EA.

Are there cheaper alternatives to DEXTROAMP-AMPHETAM 12.5 MG TAB?

No other NADAC-published product currently shares the active ingredient and strength of DEXTROAMP-AMPHETAM 12.5 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures DEXTROAMP-AMPHETAM 12.5 MG TAB?

DEXTROAMP-AMPHETAM 12.5 MG TAB (NDC 11534019301) is labeled by Sunrise Pharmaceutical Inc., and CMS classifies it as a generic product.

Is DEXTROAMP-AMPHETAM 12.5 MG TAB in shortage?

Yes — NDC 11534019301 is currently listed in FDA's drug shortage database (posted Oct 12, 2022).